|
[1]
|
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 100, S1-S276.
|
|
[2]
|
Lee, M., Suzuki, H., Nihei, Y., Matsuzaki, K. and Suzuki, Y. (2023) Ethnicity and IgA Nephropathy: Worldwide Differences in Epidemiology, Timing of Diagnosis, Clinical Manifestations, Management and Prognosis. Clinical Kidney Journal, 16, ii1-ii8.
https://doi.org/10.1093/ckj/sfad199
|
|
[3]
|
Rose-John, S. (2020) Interleukin-6 Signalling in Health and Disease. F1000 Research, 9, Article 1013.
https://doi.org/10.12688/f1000research.26058.1
|
|
[4]
|
Murakami, M., Kamimura, D. and Hirano, T. (2019) Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. Immunity, 50, 812-831.
https://doi.org/10.1016/j.immuni.2019.03.027
|
|
[5]
|
张锦鹏, 王颢典, 任华建, 等. IL-6在相关疾病中作用机制的研究进展[J]. 医学研究与战创伤救治, 2023, 36(2): 196-201.
|
|
[6]
|
Schumacher, N. and Rose-John, S. (2019) ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer. Cancers, 11, Article No. 1736.
https://doi.org/10.3390/cancers11111736
|
|
[7]
|
Rose-John, S., Jenkins, B.J., Garbers, C., Moll, J.M. and Scheller, J. (2023) Targeting IL-6 Trans-Signalling: Past, Present and Future Prospects. Nature Reviews Immunology, 23, 666-681.
https://doi.org/10.1038/s41577-023-00856-y
|
|
[8]
|
Schumertl, T., Lokau, J., Rose-John, S. and Garbers, C. (2022) Function and Proteolytic Generation of the Soluble Interleukin-6 Receptor in Health and Disease. Biochimica et Biophysica Acta—Molecular Cell Research, 1869, Article 119143.
https://doi.org/10.1016/j.bbamcr.2021.119143
|
|
[9]
|
Chandran, S. and Tang, Q. (2022) Impact of Interleukin-6 on T Cells in Kidney Transplant Recipients. American Journal of Transplantation, 22, 18-27.
https://doi.org/10.1111/ajt.17209
|
|
[10]
|
Korn, T. and Hiltensperger, M. (2021) Role of IL-6 in the Commitment of T Cell Subsets. Cytokine, 146, Article 155654.
https://doi.org/10.1016/j.cyto.2021.155654
|
|
[11]
|
Kreiner, F.F., Kraaijenhof, J.M., von Herrath, M., Hovingh, G.K.K. and von Scholten, B.J. (2022) Interleukin 6 in Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: Mechanisms and Therapeutic Perspectives. Expert Review of Clinical Immunology, 18, 377-389.
https://doi.org/10.1080/1744666x.2022.2045952
|
|
[12]
|
McElvaney, O.J., Curley, G.F., Rose-John, S. and McElvaney, N.G. (2021) Interleukin-6: Obstacles to Targeting a Complex Cytokine in Critical Illness. The Lancet Respiratory Medicine, 9, 643-654.
https://doi.org/10.1016/s2213-2600(21)00103-x
|
|
[13]
|
Huang, S.U., Kulatunge, O. and O’Sullivan, K.M. (2023) Deciphering the Genetic Code of Autoimmune Kidney Diseases. Genes, 14, Article 1028.
https://doi.org/10.3390/genes14051028
|
|
[14]
|
Institute for Health Metrics and Evaluation (IHME) (2022) GBD 2019 Cause and Risk Summary: Chronic Kidney Disease. University of Washington.
|
|
[15]
|
Wheless, L., Pike, M.M., Chen, H., Yu, Z., Tao, R., Bick, A., et al. (2022) Genetic Determinants of IL-6 Levels and Risk of ESKD. Kidney360, 4, 241-244.
https://doi.org/10.34067/kid.0003332022
|
|
[16]
|
Donate-Correa, J., Ferri, C.M., Sánchez-Quintana, F., Pérez-Castro, A., González-Luis, A., Martín-Núñez, E., et al. (2021) Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications. Frontiers in Medicine, 7, Article 628289.
https://doi.org/10.3389/fmed.2020.628289
|
|
[17]
|
Xu, S., Yang, X., Chen, Q., Liu, Z., Chen, Y., Yao, X., et al. (2022) Leukemia Inhibitory Factor Is a Therapeutic Target for Renal Interstitial Fibrosis. eBioMedicine, 86, Article 104312.
https://doi.org/10.1016/j.ebiom.2022.104312
|
|
[18]
|
Rossi, M., Korpak, K., Doerfler, A. and Zouaoui Boudjeltia, K. (2021) Deciphering the Role of Heme Oxygenase-1 (HO-1) Expressing Macrophages in Renal Ischemia-Reperfusion Injury. Biomedicines, 9, Article 306.
https://doi.org/10.3390/biomedicines9030306
|
|
[19]
|
Pfenning, M.B., Schmitz, J., Scheffner, I., Schulte, K., Khalifa, A., Tezval, H., et al. (2023) High Macrophage Densities in Native Kidney Biopsies Correlate with Renal Dysfunction and Promote ESRD. Kidney International Reports, 8, 341-356.
https://doi.org/10.1016/j.ekir.2022.11.015
|
|
[20]
|
Idasiak-Piechocka, I., Miedziaszczyk, M., Woźniak, A., Pawliczak, E., Kaczmarek, E. and Oko, A. (2023) Interleukin-6 and Epidermal Growth Factor as Noninvasive Biomarkers of Progression in Chronic Glomerulonephritis. American Journal of Physiology-Cell Physiology, 325, C1267-C1275.
https://doi.org/10.1152/ajpcell.00058.2023
|
|
[21]
|
Zheng, C., Huang, L., Luo, W., Yu, W., Hu, X., Guan, X., et al. (2019) Inhibition of STAT3 in Tubular Epithelial Cells Prevents Kidney Fibrosis and Nephropathy in STZ-Induced Diabetic Mice. Cell Death & Disease, 10, Article No. 848.
https://doi.org/10.1038/s41419-019-2085-0
|
|
[22]
|
Pandolfi, F., Franza, L., Carusi, V., Altamura, S., Andriollo, G. and Nucera, E. (2020) Interleukin-6 in Rheumatoid Arthritis. International Journal of Molecular Sciences, 21, Article 5238.
https://doi.org/10.3390/ijms21155238
|
|
[23]
|
Li, L.S., Zhao, M.M., Chang, M.Y., et al. (2024) Protective Effect of Modified Huangqi Chifeng Decoction on Immunoglobulin A Nephropathy through Toll-Like Receptor 4/Myeloid Differentiation Factor 88/Nuclear Factor-Kappa B Signaling Pathway. Journal of Traditional Chinese Medicine, 44, 324-333.
|
|
[24]
|
Gubernatorova, E.O., Samsonov, M.Y., Drutskaya, M.S., Lebedeva, S., Bukhanova, D., Materenchuk, M., et al. (2024) Targeting Inerleukin-6 for Renoprotection. Frontiers in Immunology, 15, Article 1502299.
https://doi.org/10.3389/fimmu.2024.1502299
|
|
[25]
|
Selvaskandan, H., Barratt, J. and Cheung, C.K. (2022) Immunological Drivers of IgA Nephropathy: Exploring the Mucosa-Kidney Link. International Journal of Immunogenetics, 49, 8-21.
https://doi.org/10.1111/iji.12561
|
|
[26]
|
Liang, Y., Zeng, Q., Wang, X.H., Yan, L. and Yu, R.H. (2023) Mechanism of Yiqi Yangying Heluo Formula in the Treatment of IgA Nephropathy by Affecting Gd‐IgA1 Based on BAFF Molecular Level and T Lymphocyte Immunity. BioMed Research International, 2023, Article 5124034.
https://doi.org/10.1155/2023/5124034
|
|
[27]
|
Sallustio, F., Picerno, A., Cimmarusti, M.T., Montenegro, F., Curci, C., De Palma, G., et al. (2023) Elevated Levels of IL-6 in IgA Nephropathy Patients Are Induced by an Epigenetically Driven Mechanism Modulated by Viral and Bacterial RNA. European Journal of Internal Medicine, 118, 108-117.
https://doi.org/10.1016/j.ejim.2023.07.045
|
|
[28]
|
Jemelkova, J., Stuchlova Horynova, M., Kosztyu, P., Zachova, K., Zadrazil, J., Galuszkova, D., et al. (2023) GalNAc-T14 May Contribute to Production of Galactose-Deficient Immunoglobulin A1, the Main Autoantigen in IgA Nephropathy. Kidney International Reports, 8, 1068-1075.
https://doi.org/10.1016/j.ekir.2023.02.1072
|
|
[29]
|
Tada, R., Honjo, E., Muto, S., Takayama, N., Kiyono, H., Kunisawa, J., et al. (2022) Role of Interleukin-6 in the Antigen-Specific Mucosal Immunoglobulin a Responses Induced by CpG Oligodeoxynucleotide-Loaded Cationic Liposomes. Membranes, 12, Article 635.
https://doi.org/10.3390/membranes12060635
|
|
[30]
|
Ohyama, Y., Renfrow, M.B., Novak, J. and Takahashi, K. (2021) Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don’t Know. Journal of Clinical Medicine, 10, Article 3467.
https://doi.org/10.3390/jcm10163467
|
|
[31]
|
Eslami, M., Schuepbach-Mallepell, S., Diana, D., Willen, L., Kowalczyk-Quintas, C., Desponds, C., et al. (2024) Unique and Redundant Roles of Mouse BCMA, TACI, BAFF, APRIL, and IL-6 in Supporting Antibody-Producing Cells in Different Tissues. Proceedings of the National Academy of Sciences, 121, e2404309121.
https://doi.org/10.1073/pnas.2404309121
|
|
[32]
|
Yamada, K., Huang, Z.Q., Raska, M., Reily, C., Anderson, J.C., Suzuki, H., et al. (2020) Leukemia Inhibitory Factor Signaling Enhances Production of Galactose-Deficient IgA1 in IgA Nephropathy. Kidney Diseases, 6, 168-180.
https://doi.org/10.1159/000505748
|
|
[33]
|
Luvizotto, M.J., Menezes-Silva, L., Woronik, V., Monteiro, R.C. and Câmara, N.O.S. (2022) Gut-Kidney Axis in IgA Nephropathy: Role on Mesangial Cell Metabolism and Inflammation. Frontiers in Cell and Developmental Biology, 10, Article 993716.
https://doi.org/10.3389/fcell.2022.993716
|
|
[34]
|
Xia, L., Liu, Y., Zhang, Z., Gong, Y., Yu, T., Zhao, D., et al. (2022) Modulation of IL-6 Expression by KLF4-Mediated Transactivation and PCAF-Mediated Acetylation in Sublytic C5b-9-Induced Rat Glomerular Mesangial Cells. Frontiers in Immunology, 12, Article 779667.
https://doi.org/10.3389/fimmu.2021.779667
|
|
[35]
|
Adams, D.E., Zhen, Y., Qi, X. and Shao, W. (2022) Axl Expression in Renal Mesangial Cells Is Regulated by Sp1, Ap1, MZF1, and Ep300, and the IL-6/miR-34a Pathway. Cells, 11, Article 1869.
https://doi.org/10.3390/cells11121869
|
|
[36]
|
杨永昌. 白细胞介素-6通过Src/Vav2/Rac1信号通路引起IgA肾病肾小球内皮细胞通透性增加的分子机制研究[D]: [博士学位论文]. 沈阳: 中国医科大学, 2022.
|
|
[37]
|
Xiao, J., Gong, Y., Chen, Y., Yu, D., Wang, X., Zhang, X., et al. (2017) IL-6 Promotes Epithelial-to-Mesenchymal Transition of Human Peritoneal Mesothelial Cells Possibly through the JAK2/STAT3 Signaling Pathway. American Journal of Physiology-Renal Physiology, 313, F310-F318.
https://doi.org/10.1152/ajprenal.00428.2016
|
|
[38]
|
Chaudhari, S., Yazdizadeh Shotorbani, P., Tao, Y., Davis, M.E., Mallet, R.T. and Ma, R. (2020) Inhibition of Interleukin-6 on Matrix Protein Production by Glomerular Mesangial Cells and the Pathway Involved. American Journal of Physiology-Renal Physiology, 318, F1478-F1488.
https://doi.org/10.1152/ajprenal.00043.2020
|
|
[39]
|
Chen, W., Yuan, H., Cao, W., Wang, T., Chen, W., Yu, H., et al. (2019) Blocking Interleukin-6 Trans-Signaling Protects against Renal Fibrosis by Suppressing STAT3 Activation. Theranostics, 9, 3980-3991.
https://doi.org/10.7150/thno.32352
|
|
[40]
|
Suzuki, H. and Novak, J. (2021) IgA Glycosylation and Immune Complex Formation in IgAN. Seminars in Immunopathology, 43, 669-678.
https://doi.org/10.1007/s00281-021-00883-8
|
|
[41]
|
Zhao, Q., Dai, H., Jiang, H., Zhang, N., Hou, F., Zheng, Y., et al. (2024) Activation of the IL-6/STAT3 Pathway Contributes to the Pathogenesis of Membranous Nephropathy and Is a Target for Mahuang Fuzi and Shenzhuo Decoction (MFSD) to Repair Podocyte Damage. Biomedicine & Pharmacotherapy, 174, Article 116583.
https://doi.org/10.1016/j.biopha.2024.116583
|
|
[42]
|
Su, H., Lei, C.T. and Zhang, C. (2017) Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Frontiers in Immunology, 8, Article 405.
https://doi.org/10.3389/fimmu.2017.00405
|
|
[43]
|
Nemeth, E. and Ganz, T. (2021) Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis. International Journal of Molecular Sciences, 22, Article 6493.
https://doi.org/10.3390/ijms22126493
|
|
[44]
|
Tang, D., Kang, R., Berghe, T.V., Vandenabeele, P. and Kroemer, G. (2019) The Molecular Machinery of Regulated Cell Death. Cell Research, 29, 347-364.
https://doi.org/10.1038/s41422-019-0164-5
|
|
[45]
|
Wang, Z., Shen, J., Ye, K., Zhao, J., Huang, S., He, S., et al. (2023) Neutrophil-Derived IL-6 Potentially Drives Ferroptosis Resistance in B Cells in Lupus Kidney. Mediators of Inflammation, 2023, 1-15.
https://doi.org/10.1155/2023/9810733
|
|
[46]
|
Li, M., Jin, S., Zhang, Z., Ma, H. and Yang, X. (2022) Interleukin-6 Facilitates Tumor Progression by Inducing Ferroptosis Resistance in Head and Neck Squamous Cell Carcinoma. Cancer Letters, 527, 28-40.
https://doi.org/10.1016/j.canlet.2021.12.011
|
|
[47]
|
Yang, L., Guo, J., Yu, N., Liu, Y., Song, H., Niu, J., et al. (2020) Tocilizumab Mimotope Alleviates Kidney Injury and Fibrosis by Inhibiting IL-6 Signaling and Ferroptosis in UUO Model. Life Sciences, 261, Article 118487.
https://doi.org/10.1016/j.lfs.2020.118487
|
|
[48]
|
Feng, H., Schorpp, K., Jin, J., Yozwiak, C.E., Hoffstrom, B.G., Decker, A.M., et al. (2020) Transferrin Receptor Is a Specific Ferroptosis Marker. Cell Reports, 30, 3411-3423.e7.
https://doi.org/10.1016/j.celrep.2020.02.049
|
|
[49]
|
Jhee, J.H., Nam, B.Y., Park, J.T., Kim, H.W., Chang, T.I., Kang, E.W., et al. (2021) CD71 Mesangial IgA1 Receptor and the Progression of IgA Nephropathy. Translational Research, 230, 34-43.
https://doi.org/10.1016/j.trsl.2020.10.007
|
|
[50]
|
Tian, Z.Y., Li, Z., Chu, L., Liu, Y., et al. (2023) Iron Metabolism and Chronic Inflammation in IgA Nephropathy. Renal Failure, 45, Article 2195012.
https://doi.org/10.1080/0886022x.2023.2195012
|
|
[51]
|
Zhao, W., Feng, S., Wang, Y., Wang, C., Ren, P., Zhang, J., et al. (2023) Elevated Urinary IL-6 Predicts the Progression of IgA Nephropathy. Kidney International Reports, 8, 519-530.
https://doi.org/10.1016/j.ekir.2022.12.023
|
|
[52]
|
Yoon, S.Y., Kim, J.S., Jung, S.W., Kim, Y.G., et al. (2024) Clinical Significance of Urinary Inflammatory Biomarkers in Patients with IgA Nephropathy. BMC Nephrology, 25, Article No. 142.
https://doi.org/10.1186/s12882-024-03574-2
|
|
[53]
|
Guo, X., Zhu, Y., Sun, Y. and Li, X. (2022) IL-6 Accelerates Renal Fibrosis after Acute Kidney Injury via DNMT1-Dependent FOXO3a Methylation and Activation of Wnt/β-Catenin Pathway. International Immunopharmacology, 109, Article 108746.
https://doi.org/10.1016/j.intimp.2022.108746
|
|
[54]
|
Gaumond, L., Lamarche, C., Beauchemin, S., Henley, N., Elftouh, N., Gerarduzzi, C., et al. (2024) Identification of Inflammatory Biomarkers in IgA Nephropathy Using the Nanostring Technology: A Validation Study in Caucasians. Inflammation Research, 73, 447-457.
https://doi.org/10.1007/s00011-023-01848-3
|
|
[55]
|
Chen, X., Yan, Z., Pan, Q., Zhang, C., Chen, Y., Liang, X., et al. (2024) Bibliometric Analysis of Mucosal Immunity in IgA Nephropathy from 1990 to 2022. Immunity, Inflammation and Disease, 12, e1156.
https://doi.org/10.1002/iid3.1156
|
|
[56]
|
姚楷津, 周添标. 肠道菌群与IgA肾病之间关系的研究进展[J]. 广西医学, 2025, 47(2): 192-197.
|
|
[57]
|
Makita, Y., Suzuki, H., Kano, T., Takahata, A., Julian, B.A., Novak, J., et al. (2020) TLR9 Activation Induces Aberrant IgA Glycosylation via APRIL-and IL-6-Mediated Pathways in IgA Nephropathy. Kidney International, 97, 340-349.
https://doi.org/10.1016/j.kint.2019.08.022
|
|
[58]
|
Lee, M., Suzuki, H., Ogiwara, K., Aoki, R., Kato, R., Nakayama, M., et al. (2023) The Nucleotide-Sensing Toll-Like Receptor 9/Toll-Like Receptor 7 System Is a Potential Therapeutic Target for IgA Nephropathy. Kidney International, 104, 943-955.
https://doi.org/10.1016/j.kint.2023.08.013
|
|
[59]
|
Yamada, K., Ogiwara, K., Novak, J. and Suzuki, Y. (2026) Aberrant Signaling in Tonsillar B Cells Producing Pathogenic O-Glycoforms of IgA1 in IgA Nephropathy. Frontiers in Immunology, 17, Article 1737992.
https://doi.org/10.3389/fimmu.2026.1737992
|
|
[60]
|
Kim, Y. (2026) Evolving Therapeutic Landscape of Immunoglobulin a Nephropathy: Targeted Immune Pathways and Novel Therapies. Kidney Research and Clinical Practice, 45, 677-688.
https://doi.org/10.23876/j.krcp.26.090
|